http://www.prismicpharma.com/NEUREPA_3.html Specialty Sales Representative Prismic Pharmaceuticals, Inc. - Phoenix, Arizona Area (Phoenix und Umgebung, Arizona) Stellenbeschreibung POSITION DESCRIPTION: SPECIALTY SALES REPRESENTATIVE Full time territories available; Miami FL, Atlanta GA, Raleigh/Charlotte NC, Orlando/Tampa FL Part time territories available; Jacksonville FL, Knoxville TN, New Orleans LA, Birmingham AL Under general supervision of the Vice President of Sales, the Field Sales Representative (FSR) drives business by detailing/selling pharmaceutical products to psychiatrists. FSRs employ and execute a variety of sales techniques and campaigns, all while providing superior customer service. DUTIES AND RESPONSIBILITIES: FSRs are responsible for calling on targeted psychiatrists or other key influencers such as RN’s and PA’s in their office (or other appropriate location) with the objective(s) of promoting a new prescription Medical Food, and gaining a commitment from the physician to prescribe the product, as appropriate, for their patients with Depression, Bi-Polar Disorder, and Schizophrenia. Those responsibilities also encompass the following: 1. Securing appointments with targeted psychiatrists and or making cold calls with the purpose of detailing our prescription medical food. 2. Developing and maintaining strong customer relationships with an assigned group of targeted psychiatrists, and their key members of staff. 3. Supporting and communicating the company’s programs to targeted physician practices. 4. Soliciting competitive intelligence information. 5. Contributing to the overall development and continuous improvement of the FSR’s function by sharing best practices. 6. Working in collaboration and partnership with one of the company’s Inside Video Sales Representatives to provide Psychiatrists with choices regarding the way they prefer to be detailed, and the time when they would prefer to receive those details about the company’s product. EXPERIENCE AND EDUCATIONAL REQUIREMENTS: 1. Candidates should, ideally, have a four-year college degree, preferably in the life sciences. Work experience and training in fields such as sales, marketing, pharmacy, medical practice, or similar vocations will also be taken into consideration. 2. Experience in detailing antidepressant and/or antipsychotic medications to psychiatrists in the assigned area could also be advantageous. MINIMUM SKILLS, KNOWLEDGE & ABILITY REQUIREMENTS: 1. Strong selling and negotiation skills. 2. Proven interpersonal skills; ability to make personal connections with customers while displaying a high level of integrity and ethics. 3. Articulate and courteous manner. 4. Ability to build rapport and relationships by interacting effectively with other employees and external contacts (i.e. MD and office staff) at all levels, demonstrating the awareness of their needs and responding with the appropriate action. 5. Ability to apply a range of traditional and non-traditional problem-solving techniques to think through and solve issues creatively to improve performance and company effectiveness. 6. Ability to work in a fast-paced environment and manage multiple tasks while taking ownership for territory performance, and demonstrating a competitive spirit. 7. Proven organizational skills and ability to think outside the box to achieve business success and support the achievement of team outcomes as well as a demonstrating ability to achieve personal sales objectives.
Ten years after BTG weathered a tempest as the FDA erected a barrier to its new treatment for varicose veins, the British biotech company has finally gained U.S. approval for its product and confidently predicts it can register peak sales of $500 million a year. Varithena--formerly dubbed VariSolve--is an injectable foam product designed to substitute for surgical interventions for varicose veins. And the company saw its shares shoot up 15% on the upbeat news as executives set the stage for a Q2 launch next year. "We are delighted to receive US approval for Varithena, which we believe sets a new standard for the treatment of both the symptoms and appearance of varicose veins," says CEO Louise Makin. "We look forward to the commercial US launch in the second quarter of 2014, and to continuing to advance our plans to expand use into other geographies and into non-symptomatic veins." Read more: BTG wins FDA OK for varicose vein treatment, projects $500M peak - FierceBiotech http://www.fiercebiotech.com/story/btg-wins-fda-ok-varicose-vein-treatment-projects-500m-peak/2013-11-26#ixzz2lr9cL71D Subscribe at FierceBiotech
You may have a point but have you looked at their web site, and seen the prior successes of their founders.
Probably, the money behind is from Nestle Health Science or its venture arm Inventages. They intend to make billions especially with dementia and chronic kidney disease. This company is not a joke, unfortunately. In Europe Nestle is sponoring a big Omega-3/Vitamin D/activity study in the Elderly called "do health", comparable to the NIH "Vital" study. Nevertheless, they will spend most money into marketing and not in clinical trials concentrating of RX nutritional supplements.
Stay away fro BTG & Varithena! The product actually works, but management has no clue what they're doing...not to mention they're losing $ because no one is buying a $3200.00 can of Foam....not to mention they burned bridges selling the Medicare story early on...docs lost $$ and were not reimbursed! The Brits are clueless to how the US market for Varicose Veins works! Most of the reps., with the exception of a couple who have Medicare coverage in their areas, are making no $! Pressure is building out of London to make it work, but there's no way...at least not for now.
